WaveMan
WaveMan · Company
AMLX · Amylyx Pharmaceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

AMLX Amylyx Pharmaceuticals (AMLX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001658551
Quote by TradingView
Form 144 · 6
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
120
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $170.2K priced

What the filings say about AMLX

Insiders, 180 days
-$4.3M net sold
1 buyer · 6 sellers · 8% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$5.7M
6 notices

Amylyx Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Amylyx Pharmaceuticals, Inc. insiders sold a net $4.3M of stock across 150 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
MILNE GEORGE M JR
Director
SELL
2026-10-07 SECtraded 2026-10-05
30,000
$830.9K
+4.0%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (2 buys, 2 sales), the last on Sep 3, 2024.
  • +66.5% median (+66.5% mean) 90-day return after 2 previous buys.
  • The trade is 3.8% of the 782,881 shares held after it.
  • 5 other insiders sold within 30 days.
  • 120 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MILNE GEORGE M JR sold about $830.9K of AMLX under a 10b5-1 plan on Oct 5, 2026; 5 other insiders sold within 30 days and 120 funds added in the latest 13F quarter.
Bedrosian Camille L
Chief Medical Officer
SELL
2026-09-14 SECtraded 2026-09-10
7,947
$256.0K
-14.6%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Mar 2, 2026.
  • The trade is 2.8% of the 280,145 shares held after it.
  • 5 other insiders sold within 30 days.
  • 120 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Bedrosian Camille L sold about $256.0K of AMLX on Sep 10, 2026; 5 other insiders sold within 30 days and 120 funds added in the latest 13F quarter.
Bedrosian Camille L
Chief Medical Officer
SELL
2026-09-14 SECtraded 2026-09-10
2,081
$68.9K
-14.6%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Mar 2, 2026.
  • The trade is 0.7% of the 278,064 shares held after it.
  • 5 other insiders sold within 30 days.
  • 120 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Bedrosian Camille L sold about $68.9K of AMLX on Sep 10, 2026; 5 other insiders sold within 30 days and 120 funds added in the latest 13F quarter.
FRATES JAMES M
Chief Financial Officer
SELL
2026-09-14 SECtraded 2026-09-10
9,768
$315.2K
-14.6%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (1 buy, 13 sales), the last on Mar 2, 2026.
  • The trade is 4.2% of the 234,667 shares held after it.
  • 5 other insiders sold within 30 days.
  • 120 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer FRATES JAMES M sold about $315.2K of AMLX on Sep 10, 2026; 5 other insiders sold within 30 days and 120 funds added in the latest 13F quarter.
FRATES JAMES M
Chief Financial Officer
SELL
2026-09-14 SECtraded 2026-09-10
1,042
$34.6K
-14.6%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (1 buy, 13 sales), the last on Mar 2, 2026.
  • The trade is 0.4% of the 233,625 shares held after it.
  • 5 other insiders sold within 30 days.
  • 120 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer FRATES JAMES M sold about $34.6K of AMLX on Sep 10, 2026; 5 other insiders sold within 30 days and 120 funds added in the latest 13F quarter.
150 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 145 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$4.3M over 180 days
-$3.8M over 90 days
below 78% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
120 funds bought in last quarter
more than 75% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
13.6% of the float short (float per yahoo 2026-10-27) · 9.9 days to cover · settled 2026-10-15
more than 79% of Pharma & Biotech
What changed in the last 30 days
Oct 7Director MILNE GEORGE M JR sold $830.9K under a 10b5-1 plan (Oct 5)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 5Director GEORGE MILNE filed to sell $2.8M by Oct 5 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch AMLX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+97.8%12M
-20%+45%+111%+177%2025-102025-122026-022026-042026-062026-082026-10 2026-01-15 · Cohen Joshua B sold $1.9M2026-01-15 · Klee Justin B. sold $1.8M2026-09-10 · Cohen Joshua B sold $950.0K2026-09-10 · Klee Justin B. sold $932.6K2026-10-05 · MILNE GEORGE M JR sold $830.9K2026-03-02 · Cohen Joshua B sold $424.0K2026-03-02 · Klee Justin B. sold $423.7K2026-09-10 · FRATES JAMES M sold $315.2K2026-09-10 · Mazzariello Gina sold $309.1K2026-07-09 · Mazzariello Gina sold $274.7K2026-07-10 · Mazzariello Gina sold $264.1K2026-09-10 · Bedrosian Camille L sold $256.0K2026-02-02 · Klee Justin B. sold $227.7K2026-02-02 · Cohen Joshua B sold $227.5K2026-03-02 · FRATES JAMES M sold $114.8K2025-12-23 · Firestone Karen bought $100.8K2026-03-02 · Mazzariello Gina sold $99.4K2025-12-01 · Bedrosian Camille L sold $94.4K2026-03-02 · Bedrosian Camille L sold $94.2K2026-01-06 · Cohen Joshua B sold $85.6K2026-01-06 · Klee Justin B. sold $85.6K2026-09-10 · Bedrosian Camille L sold $68.9K2026-02-02 · FRATES JAMES M sold $52.1K2026-05-21 · Firestone Karen bought $51.3K2026-02-02 · Mazzariello Gina sold $50.5K2026-02-23 · Mazzariello Gina sold $48.3K2026-09-10 · Klee Justin B. sold $47.7K2026-01-06 · FRATES JAMES M sold $37.0K2026-09-10 · FRATES JAMES M sold $34.6K2026-09-10 · Cohen Joshua B sold $30.5K2026-01-16 · Klee Justin B. sold $27.7K2026-01-16 · Cohen Joshua B sold $27.3K2026-09-10 · Mazzariello Gina sold $3672026-10-05 · GEORGE MILNE filed to sell $2.8M2026-09-11 · Cohen Joshua B filed to sell $980.5K2026-09-11 · Mazzariello Gina filed to sell $309.5K2026-09-11 · Bedrosian Camille L filed to sell $324.9K2026-09-11 · Frates James M filed to sell $349.8K2026-09-11 · Klee Justin B. filed to sell $980.3K2026-07-09 · GINA MAZZARIELLO filed to sell $536.4K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns AMLX: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
16,727,909 sh
$300.4M
BlackRock, Inc.
8,827,085 sh
$158.5M
PERCEPTIVE ADVISORS LLC
8,334,882 sh
$149.7M
TCG Crossover Management, LLC
6,243,812 sh
$112.1M
Commodore Capital LP
5,650,000 sh
$101.5M

Congress trades in AMLX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

AMLX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
GEORGE MILNE
Filed 2026-10-05
$2.8M
Cohen Joshua B
Filed 2026-09-11
$980.5K
Mazzariello Gina
Filed 2026-09-11
$309.5K
Bedrosian Camille L
Filed 2026-09-11
$324.9K
Frates James M
Filed 2026-09-11
$349.8K

AMLX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Advisor Biotechnology Fund
$49.4M position · as of 2026-07-31
2.2%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$8.7M position · as of 2026-06-30
2.0%
PROFUND VP PHARMACEUTICALS
$227.4K position · as of 2026-06-30
2.0%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$354.4K position · as of 2026-07-31
1.7%
Eventide Healthcare & Life Sciences Fund
$23.8M position · as of 2026-06-30
1.3%
Franklin Biotechnology Discovery Fund
$15.3M position · as of 2026-07-31
1.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
12 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
1 active
4
Phase 2
1 active
3
Phase 3
1 active
1
Not applicable
0 active
3
Multi-phase
0 active
What changed recently
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
2026-09-03 · Active Not Recruiting → Unknown
Phase 3
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $4.3M sold by insiders over 180 days, 120 funds added last quarter, $5.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

AMLX financials

Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-01-01 to 2025-12-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$126.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-74.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-66.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-77.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-4.0%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$0$87.4M$380.8M$22.2M
Operating income-$153.3M-$314.7M$38.8M-$201.3M
Net income-$144.7M-$301.7M$49.3M-$198.4M
EPS (diluted)-1.53-4.430.70-3.39
Operating cash flow-$123.3M-$167.6M$11.9M-$179.9M
Cash$226.7M$77.4M$170.2M$62.5M
SEC XBRL, fiscal years, as known on 2026-10-28

AMLX Stock Sonar score 5/7 axes

Find similar shapesCompare

AMLX ranks highest on institutional and government (54th percentile) and risk and compliance (44th), and lowest on growth (1st), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
37
Inputs
  • Return on equity-74.7% · 41 pct, sector of 545
  • Return on assets-66.2% · 36 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-77.8% · 34 pct, sector of 576
Growth
0
Inputs
  • Revenue growth, YoY-100.0% · 0 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
39
Inputs
  • Net Form 4 buying (codes P and S), 180d-$3.4M · 23 pct, sector of 429
  • Insider buyers, 180d1 · 56 pct, sector of 438
Institutional and government
54
Inputs
  • Funds adding, latest quarter120 · 75 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$160K · 33 pct, sector of 133
Risk and compliance
44
Inputs
  • Short interest, % of float+13.6% · 28 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+8.6% · 61 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

AMLX filings, in plain words

Are Amylyx Pharmaceuticals insiders buying or selling AMLX?

In the 180 days to 2026-10-28, Amylyx Pharmaceuticals insiders were net sellers, a net $4.3M: $51.3K of purchases and $4.3M of sales reported on Form 4, by 1 buyer and 6 sellers.

Are there planned insider sales of AMLX?

Yes. 6 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $5.7M of stock; the latest, by GEORGE MILNE, was filed 2026-10-05.

Read the full summary

In the 180 days to 2026-10-28, Amylyx Pharmaceuticals insiders were net sellers of AMLX, a net $4.3M across purchases and sales reported on Form 4 by 1 buyer and 6 sellers. Sales outweighed purchases more than tenfold by value. 8% of the 13 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 6 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $5.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies